Azienda Sanitaria Territoriale Di Pesaro E Urbino — Clinical Trial Site

33 Registered trials

21 Currently recruiting

Organisation

Azienda Sanitaria Territoriale Di Pesaro E Urbino

Location

Pesaro, Italy

Identifier

ORG-100047134

Address

Viale Vittorio Veneto 2, 61032, Italy

Departments

-
138024: Ematologia e Centro Trapianti
1510: Ematologia e Centro Trapianti
Centro di Ematologia e Trapianto del Midollo Osseo
Hematology and Stem Cell Transplant Center
Medical oncology
Onco-ematologia, UOC Ematologia e Centro Trapianti
Onco-hematology
OncoHematology
Oncologia
Oncology
U.O. Oncologia Medica
U.O.C. Oncologia
U.O.C. Oncologia Medica
U.O.C. Oncologia-Stabilimento di Pesaro
UOC Gastroenterologia e Endoscopia Digestiva
UOC Oncolog
UOC Oncologia
UOC Oncologia Medica
UOC Oncologia, OncoEmatologia
UOC Oncologia, Stabilimenti: S.Salvatore Muraglia Pesaro - S.Salvatore Centrale Pesaro-S.Croce Fano

Clinical trials at this site (33)

Search interface

HARMONi-3 Not authorised

2023-504989-37-00 Metastatic Squamous Non-small Cell Lung Cancer 5
Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inh… Not authorised

2023-505311-20-00 Metastatic Non-Small Cell Lung Cancer 5
Paclitaxel plus ramucirumab and tislelizumab as switch maintenance versus continuation of chemotherapy and tislelizumab in patients with adv… Pending

2025-524048-36-00 Advanced HER2-negative and PD-L1 positive gastroesophag 5
Phase 3 Study of Revumenib in Combination with Intensive Chemotherapy in Newly Diagnosed NPM1-mutated AML Recruiting

2025-522279-27-00 Newly Diagnosed AML with an NPM1 mutation 5 2026-04-02
A clinical study to investigate if the investigational product, called LN -145 (also known as Tumor Infiltrating Lymphocytes) is safe and be… Recruiting

2024-510778-26-00 Metastatic Non-Small-Cell Lung Cancer 4 2025-12-19
A Study to Learn About the Study Medicine Called Sigvotatug Vedotin in People with Locally Advanced, Unresectable, or Metastatic Non-Small C… Recruiting

2024-517968-36-00 non-small cell lung cancer 5 2025-07-08
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab a… Recruiting

2023-505172-29-00 Resectable Non-small Cell Lung Cancer 4 2025-04-24
An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone or in Combination with Mirikizumab for the Treatment of Adult Patients w… Recruiting

2023-507853-13-00 Ulcerative Colitis 4 2025-02-25
A Phase 3b study to learn more about the safety and tolerability of ivosidenib in combination with azacitidine in adult patients newly diagn… Recruiting

2022-501709-11-00 Isocitrate deshydrogenase1 mutation-positive (IDH1m) ac 5 2023-06-06
Phase 2 Study of Adagrasib Monotherapy and in Combination With Pembrolizumab and Phase 3 Study of Adagrasib in Combination with Pembrolizuma… Recruiting

2023-508922-83-00 Advanced Non-Small Cell Lung Cancer 10 2021-03-17
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or… Recruiting

2025-523461-17-01 LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANC 5 2026-06-01
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Ad… Recruiting

2025-521124-29-00 Non-Small Cell Lung Cancer 10 2026-02-13
Trial of Trastuzumab Deruxtecan in Combination with Pembrolizumab Versus Pembrolizumab with Platinum-based Chemotherapy in First-line HER2 o… Recruiting

2024-515658-26-00 Unresectable or Metastatic HER2 overexpressing and PD-L 5 2026-01-21
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin i… Recruiting

2024-518365-10-00 Previously Untreated Advanced or Metastatic Non-Squamou 5 2025-10-28
A phase III placebo-controlled efficacy and safety study of mocravimod as an adjunctive and maintenance treatment in AML patients undergoing… Recruiting

2024-512752-38-00 Adjunctive and maintenance treatment to HCT 5 2025-09-09
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia Recruiting

2024-520154-38-00 Acute Myeloid Luekemia 5 2025-07-29
Study of Sacituzumab Govitecan Versus Standard of Care in Participants with Previously Treated Extensive Stage Small Cell Lung Cancer Recruiting

2024-515884-69-00 Extensive Stage Small Cell Lung Cancer (ES-SCLC) 5 2025-07-16
Gemcitabine plus nab-PAclitaxel as switch maiNTEnance versus cONtinuation of modified FOLFIRINOX as first-line chemotherapy in patients with… Recruiting

2024-515214-41-00 advanced pancreatic cancer 5 2025-03-27
PRESERVE-003: ONC-392 (Study Drug) Versus Docetaxel (Standard of Care) in Metastatic Non-small Cell Lung Cancer That Progressed on PD-1/PD-L… Recruiting

2023-505311-20-01 Metastatic Non-Small Cell Lung Cancer 5 2025-03-21
Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Subjects With Metastatic Colorectal Ca… Recruiting

2022-502352-31-00 Colorectal Cancer (CRC) 5 2025-02-10
Phase III study in mCRC patients with RAS/BRAF wild type tissue and RAS/BRAF mutated in LIquid BIopsy to compare in first-line therapy FOLFI… Recruiting

2024-517863-22-00 Study population consists in patients with a diagnosis 5 2024-12-01
A multicenter single-arm phase II interventional study to evaluate the activity and safety of the combination of Platinum-Pemetrexed based c… Recruiting

2023-506714-43-00 ALK positive Non-Small Cell Lung Cancer 4 2024-03-15
Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy In HER2-positive gastric or gastroesophageal cancer patie… Recruiting

2023-506662-31-00 Gastric or gastroesophageal cancer 4 2024-02-28
Phase 2 trial of Translational approach to first line cHemoimmunotherapy followed by maintenance with pembrOlizumab and olaparib in Extensiv… Recruiting

2024-514666-39-00 Extensive-Stage Small-Cell Lung Cancer (ES SCLC) 4 2023-03-16